ANRO - candlestick chart analysis of Alto Neuroscience Inc.

Popular stocks today

AAPL BAP D JACK MSFT NVDA PDI PLTR QQQ RVPH SGOL SOXS SPY SQQQ STM TDS TER TSLA VT XLV

Membership
- Log In
- Log Out
- Sign Up
- About HotCandlestick
- Benefits
- Help
Candlestick Charts
Chart Education
Trading Tools
Opportunities
External Links

Official PayPal Seal

As Seen In...

The Complete Guide to Using Candlestick Charting: How to Earn High Rates of Return safely

End of day quotes updated Thu Dec 4 15:48 CST
🏠

⎙

🔍

◄ Daily Pattern ► ◄ Weekly Pattern ► ◄ Monthly Pattern ► ◄ Quarterly Pattern ►
Bearish In Neck Bearish Doji Star none none
14-Nov-2025 17-Apr-2025 unknown unknown
27.2 strength -537 strength

ANRO	SPY
-0.1 -3.4 -3.4 232.8 216.3	0.1 0.1 0.1 2.7 16.8
% Price Gain WTD Performance (%) MTD Performance (%) QTD Performance (%) YTD Performance (%)
SPY tracks S&P 500 index.

ANRO News
12-Nov-2025 6:57 AM CST - Business Wire Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. These past months marked a period of significant strategic execution and validation for Alto. The successful outcome
28-Oct-2025 6:34 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1
18-Aug-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events: H.C. Wainwright Biotech Breakthroughs: Precision Neuropsychiatry Panel Format: Panel discussion Presentation Date & Time: Thursday, August 21, 202
13-Aug-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. We have had an exciting past few months marked by a promising addition to our pipeline with ALTO-207 and encouraging clin
30-Jun-2025 7:03 AM CST - Business Wire Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK governments National Institute for Health and
3-Jun-2025 5:03 AM CST - Business Wire Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally
28-May-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thurs
14-May-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives, said Am
22-Apr-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presen

Disclaimer Privacy Contact

Copyright © 2001-2025, All rights reserved.
HotCandlestick.com, LLC

ANRO News
12-Nov-2025 6:57 AM CST - Business Wire Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. These past months marked a period of significant strategic execution and validation for Alto. The successful outcome
28-Oct-2025 6:34 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $anro #cns--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will present at the following upcoming investor conferences: Stifel 2025 Healthcare Conference, November 11-13, 2025 Format: Fireside chat and one-on-one meetings Presentation Date & Time: Wednesday, November 12 at 1
18-Aug-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events: H.C. Wainwright Biotech Breakthroughs: Precision Neuropsychiatry Panel Format: Panel discussion Presentation Date & Time: Thursday, August 21, 202
13-Aug-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. We have had an exciting past few months marked by a promising addition to our pipeline with ALTO-207 and encouraging clin
30-Jun-2025 7:03 AM CST - Business Wire Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry publication of data from the PAX-D study evaluating pramipexole in patients with treatment-resistant depression (TRD). The study was conducted by the University of Oxford and was funded by the UK governments National Institute for Health and
3-Jun-2025 5:03 AM CST - Business Wire Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally
28-May-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thurs
14-May-2025 3:10 PM CST - Business Wire Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives, said Am
22-Apr-2025 7:03 AM CST - Business Wire Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presen